Table 2.
Proton pump inhibitor and histamine-2 receptor antagonist use in hip fracture cases and controls and measures of association
| Acid Suppressant | Proportion of Days Covered | Cases (n=4551), N (%) | Controls (n=45,510), N (%) | Unadjusted Odds Ratio | P Value | Adjusted Odds Ratio | P Value |
|---|---|---|---|---|---|---|---|
| Proton pump inhibitor | No use | 1347 (30) | 16,773 (37) | 1.00 (referent) | – | 1.00 (referent) | – |
| Any use | 3204 (70) | 28,737 (63) | 1.39 (1.30 to 1.49) | <0.001 | 1.19 (1.11 to 1.28) | <0.001 | |
| <20% PDC | 906 (19) | 9325 (21) | 1.21 (1.11 to 1.32) | <0.001 | 1.16 (1.06 to 1.27) | <0.001 | |
| ≥20% and <80% PDC | 1483 (33) | 12,864 (28) | 1.44 (1.33 to 1.55) | <0.001 | 1.21 (1.11 to 1.31) | <0.001 | |
| ≥80% PDC | 815 (18) | 6548 (14) | 1.55 (1.42 to 1.70) | <0.001 | 1.19 (1.08 to 1.31) | <0.001 | |
| H2-receptor antagonist | No use | 3429 (75) | 35,011 (77) | 1.00 (referent) | – | 1.00 (referent) | – |
| Any use | 1122 (25) | 10,499 (23) | 1.09 (1.02 to 1.17) | 0.02 | 1.02 (0.95 to 1.10) | 0.54 | |
| <20% PDC | 568 (13) | 5755 (13) | 1.01 (0.92 to 1.11) | 0.87 | 0.99 (0.90 to 1.09) | 0.09 | |
| ≥20% and <80% PDC | 431 (10) | 3378 (8) | 1.23 (1.11 to 1.37) | <0.001 | 1.08 (0.97 to 1.21) | 0.20 | |
| ≥80% PDC | 123 (3) | 1166 (3) | 1.08 (0.89 to 1.30) | 0.44 | 0.96 (0.79 to 1.17) | 0.16 |
PDC, proportion of days covered (sum of the number of days of drug supplied in prescriptions divided by the number of days of the interval; here: 1095 days).